NOD/SCID IL2R gamma-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines

Investor logo
Investor logo

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

VERNER Jan TRBUŠEK Martin CHOVANCOVÁ Jana JAŠKOVÁ Zuzana MOULIS Mojmír FOLBER František HALOUZKA Roman MAYER Jiří POSPÍŠILOVÁ Šárka DOUBEK Michael

Year of publication 2015
Type Article in Periodical
Magazine / Source Leukemia & Lymphoma
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.3109/10428194.2015.1034701
Field Oncology and hematology
Keywords chronic lymphocytic leukemia; mantle cell lymphoma; NSG mouse; xenograft model
Attached files
Description Xenograft models represent a promising tool to study the pathogenesis of hematological malignancies. To establish a reliable and appropriate in vivo model of aggressive human B-cell leukemia and lymphoma we xenotransplanted four p53-mutated cell lines and one ATM-mutated cell line into immunodeficient NOD/SCID IL2R gamma-null mice. The cell lines MEC-1, SU-DHL-4, JEKO-1, REC-1, and GRANTA-519 were transplanted intraperitoneally or subcutaneously and the engraftment was investigated using immunohistochemistry and flow cytometry. We found significant differences in engraftment efficiency. MEC-1, JEKO-1 and GRANTA-519 cell lines engrafted most efficiently, while SU-DHL-4 cells did not engraft at all. MEC-1 and GRANTA-519 massively infiltrated organs and the whole intraperitoneal cavity showing very aggressive growth. In addition, GRANTA-519 cells massively migrated to the bone marrow regardless of the transplantation route. The MEC-1 and GRANTA-519 cells can be especially recommended for in vivo study of p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma, respectively.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info